Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity.
C9orf72
CSF
GRN
MAPT
frontotemporal dementia
galectin-3
microglia
neuroinflammation
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
04
10
2023
received:
26
06
2023
accepted:
11
10
2023
medline:
18
3
2024
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
ppublish
Résumé
Neuroinflammation is a major contributor to the progression of frontotemporal dementia (FTD). Galectin-3 (Gal-3), a microglial activation regulator, holds promise as a therapeutic target and potential biomarker. Our study aimed to investigate Gal-3 levels in patients with FTD and assess its diagnostic potential. We examined Gal-3 levels in brain, serum, and cerebrospinal fluid (CSF) samples of patients with FTD and controls. Multiple linear regressions between Gal-3 levels and other FTD markers were explored. Gal-3 levels were increased significantly in patients with FTD, mainly across brain tissue and CSF, compared to controls. Remarkably, Gal-3 levels were higher in cases with tau pathology than TAR-DNA Binding Protein 43 (TDP-43) pathology. Only MAPT mutation carriers displayed increased Gal-3 levels in CSF samples, which correlated with total tau and 14-3-3. Our findings underscore the potential of Gal-3 as a diagnostic marker for FTD, particularly in MAPT cases, and highlights the relation of Gal-3 with neuronal injury markers.
Substances chimiques
Galectin 3
0
tau Proteins
0
Biomarkers
0
C9orf72 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1515-1526Subventions
Organisme : Instituto de Salud Carlos III
ID : PI20/0448
Organisme : Instituto de Salud Carlos III
ID : PI18/01556
Organisme : Instituto de Salud Carlos III
ID : PI21/00914
Organisme : Una manera de hacer Europa
ID : PI19/00449
Organisme : Generalitat de Catalunya
ID : SGR 2021-01126
Organisme : Vetenskapsrådet
ID : 2019-0633
Organisme : Kungliga Fysiografiska Sällskapet i Lund
ID : 20191114ABS
Organisme : Kungliga Fysiografiska Sällskapet i Lund
ID : 20211129ABS
Organisme : Greta och Johan Kocks stiftelser
ID : 20201201ABS
Organisme : Juan de la Cierva Incorporación
ID : IJC2019-040731-I
Organisme : Spanish Ministerio de Ciencia e Innovación /FEDER/UE
ID : PID2021-124096OB-I00
Organisme : Swedish Demensfonden
Organisme : Swedish Brain Foundation
Organisme : Crafoord Foundation
Organisme : Swedish Dementia Association
Organisme : G&J Kock Foundation
Organisme : Olle Engkvist Foundation
Organisme : Gamla Tjänarinnor Foundation
Organisme : Swedish Medical Research Council
Organisme : Swedish Parkinson Foundation
Organisme : Swedish Parkinson Research Foundation
Organisme : A.E. Berger Foundation
Informations de copyright
© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol. 2012;8(8):423-434. doi:10.1038/nrneurol.2012.117
Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58(11):1615-1621. doi:10.1212/wnl.58.11.1615
Garre-Olmo J, Genis Batlle D, del Mar Fernandez M, et al. Incidence and subtypes of early-onset dementia in a geographically defined general population. Neurology. 2010;75(14):1249-1255. doi:10.1212/WNL.0b013e3181f5d4c4
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477. doi:10.1093/brain/awr179
Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6
Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2019;266(8):2075-2086. doi:10.1007/s00415-019-09363-4
Moore KM, Nicholas J, Grossman M, et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol. 2020;19(2):145-156. doi:10.1016/S1474-4422(19)30394-1
Neumann M, Mackenzie IRA. Review: neuropathology of non-tau frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. 2019;45(1):19-40. doi:10.1111/nan.12526
Kovacs GG. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2015;41(1):3-23. doi:10.1111/nan.12208
Bright F, Werry EL, Dobson-Stone C, et al. Neuroinflammation in frontotemporal dementia. Nat Rev Neurol. 2019;15(9):540-555. doi:10.1038/s41582-019-0231-z
Malpetti M, Cope TE, Street D, et al. Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia. Brain. 2023;146(8):3221-3231. doi:10.1093/brain/awad078
Malpetti M, Rittman T, Jones PS, et al. In vivo PET imaging of neuroinflammation in familial frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2021;92(3):319-322. doi:10.1136/jnnp-2020-323698
Cagnin A, Rossor M, Sampson EL, Mackinnon T, Banati RB. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol. 2004;56(6):894-897. doi:10.1002/ana.20332
Kim MJ, McGwier M, Jenko KJ, et al. Neuroinflammation in frontotemporal lobar degeneration revealed by (11) C-PBR28 PET. Ann Clin Transl Neurol. 2019;6(7):1327-1331. doi:10.1002/acn3.50802
Woollacott IOC, Toomey CE, Strand C, et al. Microglial burden, activation and dystrophy patterns in frontotemporal lobar degeneration. J Neuroinflammation. 2020;17(1):234. doi:10.1186/s12974-020-01907-0
Taipa R, Brochado P, Robinson A, et al. Patterns of microglial cell activation in Alzheimer disease and frontotemporal lobar degeneration. Neurodegener Dis. 2017;17(4-5):145-154. doi:10.1159/000457127
Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer's disease. Cell. 2017;169(7):1276-1290 e17. doi:10.1016/j.cell.2017.05.018
Krasemann S, Madore C, Cialic R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47(3):566-581 e9. doi:10.1016/j.immuni.2017.08.008
Garcia-Revilla J, Boza-Serrano A, Espinosa-Oliva AM, et al. Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration. Cell Death Dis. 2022;13(7):628. doi:10.1038/s41419-022-05058-3
Burguillos MA, Svensson M, Schulte T, et al. Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep. 2015;10(9):1626-1638. doi:10.1016/j.celrep.2015.02.012
Boza-Serrano A, Ruiz R, Sanchez-Varo R, et al. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer's disease. Acta Neuropathol. 2019;138(2):251-273. doi:10.1007/s00401-019-02013-z
Garcia-Revilla J, Boza-Serrano A, Jin Y, et al. Galectin-3 shapes toxic alpha-synuclein strains in Parkinson's disease. Acta Neuropathol. 2023;146(1):51-75. doi:10.1007/s00401-023-02585-x
Boza-Serrano A, Reyes JF, Rey NL, et al. The role of Galectin-3 in alpha-synuclein-induced microglial activation. Acta Neuropathol Commun. 2014;2:156. doi:10.1186/s40478-014-0156-0
Boza-Serrano A, Vrillon A, Minta K, et al. Galectin-3 is elevated in CSF and is associated with Abeta deposits and tau aggregates in brain tissue in Alzheimer's disease. Acta Neuropathol. 2022;144(5):843-859. doi:10.1007/s00401-022-02469-6
Johnson ECB, Dammer EB, Duong DM, et al. Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med. 2020;26(5):769-780. doi:10.1038/s41591-020-0815-6
Yin F, Dumont M, Banerjee R, et al. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J. 2010;24(12):4639-4647. doi:10.1096/fj.10-161471
Yin F, Banerjee R, Thomas B, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010;207(1):117-128. doi:10.1084/jem.20091568
Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337-351. doi:10.1016/j.neuron.2007.01.010
Huang M, Modeste E, Dammer E, et al. Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations. Acta Neuropathol Commun. 2020;8(1):163. doi:10.1186/s40478-020-01037-x
Zambusi A, Novoselc KT, Hutten S, et al. TDP-43 condensates and lipid droplets regulate the reactivity of microglia and regeneration after traumatic brain injury. Nat Neurosci. 2022;25(12):1608-1625. doi:10.1038/s41593-022-01199-y
Kersaitis C, Halliday GM, Kril JJ. Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathol. 2004;108(6):515-523. doi:10.1007/s00401-004-0917-0
Arnold SE, Han LY, Clark CM, Grossman M, Trojanowski JQ. Quantitative neurohistological features of frontotemporal degeneration. Neurobiol Aging. 2000;21(6):913-919. doi:10.1016/s0197-4580(00)00173-1
Maya G, Sarto J, Compta Y, et al. Assessment of cognitive symptoms in brain bank-registered control subjects: feasibility and utility of a telephone-based screening. J Alzheimers Dis. 2022;85(3):1107-1113. doi:10.3233/JAD-215444
Yazar T, Olgun Yazar H, Cihan M. Evaluation of serum galectin-3 levels at Alzheimer patients by stages: a preliminary report. Acta Neurol Belg. 2021;121(4):949-954. doi:10.1007/s13760-020-01477-1
Schmitz M, Ebert E, Stoeck K, et al. Validation of 14-3-3 protein as a marker in sporadic creutzfeldt-jakob disease diagnostic. Mol Neurobiol. 2016;53(4):2189-2199. doi:10.1007/s12035-015-9167-5
Gaetani L, Hoglund K, Parnetti L, et al. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimers Res Ther. 2018;10(1):8. doi:10.1186/s13195-018-0339-1
Willemse EAJ, De Vos A, Herries EM, et al. Neurogranin as cerebrospinal fluid biomarker for Alzheimer disease: an assay comparison study. Clin Chem. 2018;64(6):927-937. doi:10.1373/clinchem.2017.283028
Nordengen K, Kirsebom BE, Henjum K, et al. Glial activation and inflammation along the Alzheimer's disease continuum. J Neuroinflammation. 2019;16(1):46. doi:10.1186/s12974-019-1399-2
Liu FT, Rabinovich GA. Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci. 2010;1183:158-182. doi:10.1111/j.1749-6632.2009.05131.x
Pesamaa I, Muller SA, Robinson S, et al. A microglial activity state biomarker panel differentiates ftd-granulin and Alzheimer's disease patients from controls. bioRxiv. 2023;06(15):545187. doi:10.1101/2023.06.15.545187. bioRxiv.
Starossom SC, Mascanfroni ID, Imitola J, et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity. 2012;37(2):249-263. doi:10.1016/j.immuni.2012.05.023
Steelman AJ, Li J. Astrocyte galectin-9 potentiates microglial TNF secretion. J Neuroinflammation. 2014;11:144. doi:10.1186/s12974-014-0144-0
Burman J, Svenningsson A. Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. J Neuroimmunol. 2016;292:40-44. doi:10.1016/j.jneuroim.2016.01.008
Premeaux TA, D'Antoni ML, Abdel-Mohsen M, et al. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. J Neurovirol. 2019;25(2):150-161. doi:10.1007/s13365-018-0696-3
Guerreiro RJ, Lohmann E, Bras JM, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013;70(1):78-84. doi:10.1001/jamaneurol.2013.579
Rayaprolu S, Mullen B, Baker M, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener. 2013;8:19. doi:10.1186/1750-1326-8-19
Lill CM, Rengmark A, Pihlstrom L, et al. The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimers Dement. 2015;11(12):1407-1416. doi:10.1016/j.jalz.2014.12.009
Johnson AM, Lukens JR. The innate immune response in tauopathies. Eur J Immunol. 2023;53(6):e2250266. doi:10.1002/eji.202250266
Lant SB, Robinson AC, Thompson JC, et al. Patterns of microglial cell activation in frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. 2014;40(6):686-696. doi:10.1111/nan.12092
Borrego-Ecija S, Morgado J, Palencia-Madrid L, et al. Frontotemporal dementia caused by the P301L mutation in the MAPT gene: clinicopathological features of 13 cases from the same geographical origin in Barcelona, Spain. Dement Geriatr Cogn Disord. 2017;44(3-4):213-221. doi:10.1159/000480077
Hartnell IJ, Blum D, Nicoll JAR, Dorothee G, Boche D. Glial cells and adaptive immunity in frontotemporal dementia with tau pathology. Brain. 2021;144(3):724-745. doi:10.1093/brain/awaa457
van Olst L, Verhaege D, Franssen M, et al. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model. Neurobiol Aging. 2020;89:89-98. doi:10.1016/j.neurobiolaging.2020.01.003
Karlsson A, Christenson K, Matlak M, et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology. 2009;19(1):16-20. doi:10.1093/glycob/cwn104
Karlsson M, Zhang C, Mear L, et al. A single-cell type transcriptomics map of human tissues. Sci Adv. 2021;7(31):eabh2169. doi:10.1126/sciadv.abh2169
Lo TH, Chen HL, Yao CI, et al. Galectin-3 promotes noncanonical inflammasome activation through intracellular binding to lipopolysaccharide glycans. Proc Natl Acad Sci U S A. 2021;118(30):e2026246118. doi:10.1073/pnas.2026246118
Gao X, Liu J, Liu X, Li L, Zheng J. Cleavage and phosphorylation: important post-translational modifications of galectin-3. Cancer Metastasis Rev. 2017;36(2):367-374. doi:10.1007/s10555-017-9666-0
Nabi IR, Shankar J, Dennis JW. The galectin lattice at a glance. J Cell Sci. 2015;128(13):2213-2219. doi:10.1242/jcs.151159
Hara A, Niwa M, Kanayama T, et al. Galectin-3: a potential prognostic and diagnostic marker for heart disease and detection of early stage pathology. Biomolecules. 2020;10(9):1277. doi:10.3390/biom10091277
Bevan-Jones WR, Cope TE, Jones PS, et al. In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier. Ann Clin Transl Neurol. 2019;6(2):373-378. doi:10.1002/acn3.683
Shi Y, Manis M, Long J, et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med. 2019;216(11):2546-2561. doi:10.1084/jem.20190980
Antonell A, Tort-Merino A, Rios J, et al. Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimers Dement. 2020;16(2):262-272. doi:10.1016/j.jalz.2019.09.001
Nilsson J, Cousins KAQ, Gobom J, et al. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders. Alzheimers Dement. 2023;19(5):1775-1784. doi:10.1002/alz.12809
Das S, Goossens J, Jacobs D, et al. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia. Alzheimers Res Ther. 2023;15(1):62. doi:10.1186/s13195-023-01212-x
Hong S, Beja-Glasser VF, Nfonoyim BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352(6286):712-716. doi:10.1126/science.aad8373
Heller C, Foiani MS, Moore K, et al. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020;91(3):263-270. doi:10.1136/jnnp-2019-321954
Zhang J, Velmeshev D, Hashimoto K, et al. Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency. Nature. 2020;588(7838):459-465. doi:10.1038/s41586-020-2709-7
Woollacott IOC, Swift IJ, Sogorb-Esteve A, et al. CSF glial markers are elevated in a subset of patients with genetic frontotemporal dementia. Ann Clin Transl Neurol. 2022;9(11):1764-1777. doi:10.1002/acn3.51672
Sarto J, Ruiz-Garcia R, Guillen N, et al. Diagnostic performance and clinical applicability of blood-based biomarkers in a prospective memory clinic cohort. Neurology. 2023;100(8):e860-e873. doi:10.1212/WNL.0000000000201597
Illan-Gala I, Lleo A, Karydas A, et al. Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease. Neurology. 2021;96(5):e671-e683. doi:10.1212/WNL.0000000000011226
van der Ende EL, Meeter LH, Poos JM, et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 2019;18(12):1103-1111. doi:10.1016/S1474-4422(19)30354-0
Meeter LHH, Steketee RME, Salkovic D, et al. Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. J Neurol Neurosurg Psychiatry. 2019;90(9):997-1004. doi:10.1136/jnnp-2018-319784